🌟 Cheerful News Daily

In a 659-patient phase 3 trial, both doses of Cloudbreak Pharma's CBT-001 eye drops eased redness and limited growth of pterygium, an eye condition only surgery can remove. Here is what the company's topline data show, what the drops cost in side effects, and why independent review still matters.

A study of every bird and mammal species that fell below 50 wild animals since 1950 found that 61% of those given direct conservation help recovered to at least 100. Here is what the help looked like, how one island bird came back from about 23, and what the study cannot prove.

The FDA gave tentative approval to a generic twice-yearly HIV prevention shot that will cost $40 per person per year in 120 countries, about 16 months after the brand-name version was approved. Here is what the trials show, how the timeline shrank, and what still stands between approval and patients.

In a phase 3 trial of 1,137 people, a personalized mRNA vaccine added to pembrolizumab after melanoma surgery lowered the risk of recurrence or death by 42%. Here is what the trial shows, why the first six months looked the same, and what is still open.

In a randomized trial of 236 adults with Ph-positive acute lymphoblastic leukemia, a regimen with no chemotherapy had higher event-free survival at 24 months than imatinib plus chemotherapy, 86% against 67%. Here is what the trial shows, why overall survival differs by less, and what is still open.

Nine private funders announced the Species Recovery Alliance at COP17, committing more than $500 million over five years to species classed as extinct in the wild, critically endangered, or endangered. Here is what the pledge covers, how it sits beside total nature funding, and what the sources do not yet say.